For U.S Healthcare Professionals Only

ARCALYST (rilonacept) for injection

DESIGNED TO SIMPLIFY ACCESS TO TREATMENT FOR YOU AND YOUR PATIENTS

Starting Your Patients on ARCALYST® (rilonacept)

Initiating treatment

  • ARCALYST should not be initiated in patients with an active or chronic infection.
  • Ensure your patient’s vaccination history is up-to-date, including pneumonia and flu vaccines.
  • Refer to current practice guidelines for evaluation and treatment of possible latent tuberculosis infections before initiating ARCALYST.

Enrollment completion

By completing an Enrollment Form, your patient may be eligible to receive Kiniksa OneConnect™ program benefits, such as financial assistance and injection training. The Enrollment Form also serves as a prescription for ARCALYST.

Download and complete the ARCALYST enrollment form

Enrollment Form in English Enrollment Form in Spanish

Enrollment Forms are also available from your Clinical Sales Specialist.

Fax completed enrollment form to the Kiniksa OneConnect™ program at 781-609-7826

Comprehensive Support Throughout the Treatment Journey

The Kiniksa OneConnect™ program is designed to simplify the treatment experience for your practice and your patients.

Once you have enrolled your patient in the program, a dedicated Patient Access Lead (PAL) will be the point of contact for both you and your patient throughout their treatment journey.

Reimbursement Support

Insurance Coverage and Benefits Investigation

After verifying benefits with the insurer, the PAL will provide both you and your patient a summary of benefits, including the patient’s copay responsibility.

Prior Authorization (PA) Support

We’ll inform your office if a PA is required, including documentation required and how to submit.

Appeals Support

If you receive notification that coverage has been denied, your PAL can provide a guide with sample letter template for submitting a Letter of Appeal to the insurer.

Financial Assistance Programs

Commercial Copay Assistance Program*

Eligible, commercially insured patients pay as little as $0 per month for treatment

Quick Start Program†

Supports eligible patients with delay in coverage for treatment initiation  

  • Program offered at no cost for up to 60 days while awaiting PA

Patient Assistance Program‡

Supports eligible patients with limited or no coverage for treatment

  • Qualified patients can receive treatment at no cost for up to 12 months

Eligibility requirements, terms and conditions, and  restrictions apply.

  • To be eligible for the Kiniksa Copay Assistance Program, your patients must have commercial insurance, must not have Medicare, Medicaid, or other government insurance, and must meet other eligibility criteria. Your patient also must agree to the rules set forth in the terms and conditions for the program. Please visit kiniksapolicies.com/copay to review additional eligibility criteria.
  • Program offered for up to 60 days. To be eligible for the Kiniksa Quick Start Program, your patient must meet certain financial eligibility requirements. Please visit kiniksapolicies.com/qstart to review additional eligibility criteria.
  • Program offered for up to 12 months. Please visit kiniksapolicies.com/pap to review additional eligibility criteria.

    • Injection Training and Support

    The Kiniksa OneConnect™ program supports a variety of injection training options to help ensure that patients feel confident with preparing and injecting their ARCALYST® (rilonacept) treatment.

    In-office training by you or your office  staff

    One-on-one injection training  (virtual or in person) with an ARCALYST Clinical Educator

    Ongoing Treatment Support

    Clinical Education Support

    An ARCALYST Clinical Educator will reach out to your patient at regular intervals to reinforce the injection training and answer questions throughout their ARCALYST treatment journey. 

    Patient Access Lead Support

    The dedicated PAL will check in with your patient regarding ARCALYST refill ordering and deliveries to help minimize treatment interruptions. 

    Welcome to the Kiniksa OneConnect Program guide

    Help your patients learn more about our services.

    Download
    KINIKSA OneConnect

    Call 1-833-KINIKSA (1-833-546-4572), Option 1
    Monday-Friday (8 AM – 8 PM ET)

    See Payer Access Information for ARCALYST
    Request to speak to a Clinical Sales Specialist

    Indication

    ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

    • Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
    • Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older. 
    • Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

    Important Safety Information

    Warnings and Precautions

    • Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with an active or chronic infection.
    • Discontinue ARCALYST if a patient develops a serious infection.
    • It is possible that taking drugs such as ARCALYST that block IL-1 may increase the risk of tuberculosis (TB) or other atypical or opportunistic infections.
    • Although the impact of ARCALYST on infections and the development of malignancies is not known, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of malignancies.
    • Hypersensitivity reactions associated with ARCALYST occurred in clinical trials. Discontinue ARCALYST and initiate appropriate therapy if a hypersensitivity reaction occurs. 
    • Increases in non-fasting lipid profile parameters occurred in patients treated with ARCALYST in clinical trials. Patients should be monitored for changes in their lipid profiles.
    • Since no data are available, avoid administration of live vaccines while patients are receiving ARCALYST. ARCALYST may interfere with the normal immune response to new antigens, so vaccines may not be effective in patients receiving ARCALYST. It is recommended that, prior to initiation of therapy with ARCALYST, patients receive all recommended vaccinations, as appropriate.

    Adverse Reactions

    • In patients with CAPS or RP, the most common adverse reactions (≥10%) include injection-site reactions and upper respiratory tract infections.
    • In patients with DIRA, the most common adverse reactions (>10%) include upper respiratory tract infections, rash, otitis media, pharyngitis, and rhinorrhea.

    Drug Interactions

    • In patients being treated with CYP450 substrates with narrow therapeutic indices, therapeutic monitoring of the effect or drug concentration should /pi.pdfbe performed, and the individual dose of the medicinal product may need to be adjusted.

    For more information about ARCALYST, see full Prescribing Information.